Effect of Dexmedetomidine for Palliative Sedation for Refractory Dyspnoea in Patients with Terminal-Stage Cancer.

Na LiMeng CuiYumei Wang

Published in: Cancer management and research (2023)

DEX is a promising palliative sedative for patients with terminal-stage cancer, as it safely relieved the symptoms of refractory dyspnoea without inducing serious adverse reactions. Therefore, DEX may greatly enhance the quality of life for patients with terminal-stage cancer.

Keyphrases

papillary thyroid
squamous cell
lymph node metastasis
squamous cell carcinoma
intensive care unit
emergency department
drug induced